AWAK Technologies relocates to new HQ in Singapore

By Murielle Gonzalez | Published: 16-Jul-2018

The 6,000 square foot headquarters houses a cleanroom manufacturing facility and fully-equipped chemistry and engineering laboratories

AWAK Technologies (AWAK), a medical technology company focused on dialysis using regeneration technology for end-stage renal disease, has moved to its new headquarters in Singapore. The relocation aims to strengthen its presence in the region to support growth over the next few years.

The new 6,000 square foot office in Tuas houses 16 employees in research, regulatory and business development functions. AWAK said the new HQ features a fully-equipped chemistry lab, engineering lab and a cleanroom manufacturing facility to support the company’s research, development, manufacturing and commercial activities.

AWAK’s move to its new headquarters follows the appointment of its new management team in late-2017. Led by chief executive officer Suresh Venkataraya, the management team consists of:

  • Mandar Gori, Director of Marketing and Business Development
  • Daniel Tan, Director of Program Management and Operations
  • Joel Preetham Fernandes, Director of R&D and Quality
  • Carol Lim, Head of Finance and HR
The new management team has a combined global commercial experience of close to 50 years in medical devices covering R&D, Finance, QA/RA, supply chain, manufacturing, sales, marketing and FDA and CE approvals, and underscores AWAK’s vision in bringing its patented sorbent technology that enables the development of ultra-portable peritoneal and haemodialysis machines to market globally.

AWAK has also recently formed a Technical Advisory Committee, which will provide scientific guidance and advice on product development, comprised of senior advisors who are scientific experts in biochemistry, biopharmaceuticals and commercialisation of dialysis technologies.

CEO Venkataraya commented: “We have made significant progress in recent years, including securing financing from Southeast Asia’s largest medtech company, Accuron MedTech, which will accelerate the research and development of our product. We expect to complete our first-in-human trial this quarter, a significant milestone for AWAK.

"I am excited about AWAK’s next phase of growth as we look to bring our revolutionary technology to markets globally and change the lives of end-stage renal disease patients worldwide," he concluded.

Headquartered in Singapore with an office in Burbank, California (US,) Awak is dedicated to the research, development and marketing of novel, sorbent-based kidney dialysis machine for the treatment of patients with end-stage renal disease.

Trending Articles

You may also like